NOW APPROVED for resected EGFRm NSCLC NOW APPROVEDfor resected EGFRm NSCLC

ADJUVANT TAGRISSO DELIVERS
GROUNDBREAKING EFFICACY

In patients with Stage II to IIIA
resected EGFRm NSCLC (primary endpoint),

adjuvant TAGRISSO reduced the
risk of recurrence or death by
83%

vs placebo (HR=0.17 [99.06% CI: 0.11, 0.26];
P<0.001)1

TAGRISSO AS MONOTHERAPY IS INDICATED FOR:

  • the adjuvant treatment after complete tumour resection in adult patients with stage IB-IIIA non-small cell lung cancer (NSCLC) whose tumours have epidermal growth factor receptor (EGFR) exon 19 deletions or exon 21 (L858R) substitution mutations.
  • the first-line treatment of adult patients with locally advanced or metastatic NSCLC with activating EGFR mutations.
  • the treatment of adult patients with locally advanced or metastatic EGFR T790M mutation-positive NSCLC.

Reference: 1. Wu Y-L, Tsuboi M, He J, et al; ADAURA Investigators. Osimertinib in resected EGFR-mutated non–small-cell lung cancer. N Engl J Med. 2020. doi:10.1056/NEJMoa2027071.